Definitive Contract 75N91025C00039
Award Date
9/15/25
Potential Completion Date
9/14/26
Potential Value
$354K
Federal Agency
National Cancer Institute
Awardee
Matrisome Bio, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02139, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
55
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
<p>This is a $299,813 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Hylapharm LLC, a self-certified small disadvantaged business, under the SBIR Program Phase I. The contract is for the development of "Targeted Nanoparticle Treatment for Breast Cancer Stem Cells." This contract has a Total Small Business set-aside designation. The contract has an ultimate completion date of September 17, 2016.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services' National Institutes of Health, to Radiomedix, Inc., a small disadvantaged business. The contract, valued at $1,994,002.00, is for the development of targeted radionuclide therapy using 212Pb-octreotate analogs for the treatment of neuroendocrine tumors. The contract was awarded on September 18, 2018 and has a completion date of...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency under the U.S. Department of Health and Human Services. The contract, valued at $298,601, was awarded to Mediomics LLC, a woman-owned small business, for the "Development of Blood-Based Methods for the Detection of Cancer Recurrence in Post-Therapy Breast Cancer Patients." The contract was set aside for small businesses and is a Definitive Contract...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract, valued at $185,116, is a firm-fixed-price definitive contract for research and development work. The contract was awarded on September 24, 2010 and has an ultimate completion date of June 23, 2011. As an SBIR Phase I contract, it is focused on the early-stage feasibility study of a...
<p>This is a Phase I Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency, to Sibtech, Inc., a for-profit manufacturer, in the amount of $2,256,052.35. The contract is for the development of systemic radionuclide therapy targeted to VEGF receptors in tumor vasculature. The contract has a firm fixed price pricing type and an ultimate completion date of October 31, 2021. This contract is a set-aside for small businesses.</p>
<p>This is a $199,969 Small Business Innovation Research (SBIR) Program Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Accelerated Medical Diagnostics, Inc. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type with a completion date of September 30, 2016. As an SBIR Phase I award, this contract supports early-stage research and development activities.</p>
This is a $455,000 firm fixed price contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS). The contract was awarded to Mrimath LLC, a small disadvantaged, woman-owned limited liability company, for a Small Business Innovation Research (SBIR) Phase I project related to Artificial Intelligence-aided imaging for cancer prevention, diagnosis, and monitoring. The contract has a...